MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression

Chun Ming Shih, Yung Hsiang Chen, Yi Wen -Lin, Nai Wen Tsao, Shinn Chih Wu, Yung Ta Kao, Kuang Hsing Chiang, Chi Yuan Li, Nen Chung Chang, Cheng Yen Lin, Chun Yao Huang, Feng Yen Lin

研究成果: 雜誌貢獻文章

18 引文 (Scopus)

摘要

Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic vasculogenesis may open an important new avenue for the treatment of CLI. This study examines the therapeutic potential of the DPP-4 inhibitor MK-0626 as a regulator of vasculogenesis in vivo. MK-0626 was administered daily to C57CL/B6 mice and eGFP-labeled bone marrow-transplanted ICR mice that had undergone hind limb ischemia surgery. Laser Doppler imaging and flow cytometry were used to evaluate the degree of neo-vasculogenesis and the number of circulating endothelial progenitor cells (EPCs), respectively. Cell surface markers of EPCs and the level of endothelial nitric oxide synthase (eNOS) were studied in the vessels. Mice that received MK-0626 had an elevated level of glucagon- like peptide-1 (GLP-1) and a decreased level of dipeptidyl peptidase-4 (DPP-4) in their plasma, in addition to an ischemia-induced increase in the level of stromal cell-derived factor-1 (SDF-1). In C57CL/B6 mice, blood flow in the ischemic limb was significantly improved by treatment with MK-0626. The number of circulating EPCs and both the synthesis and phosphorylation of eNOS were also increased in ischemic thigh muscle after MK-0626 treatment. In contrast, similar effects of MK-0626 were not observed in B6.129P2-Nos3tm1Unc/J mice (an eNOS knockout mouse). Additionally, MK-0626 treatment promoted the mobilization and homing of EPCs to ischemic tissue in eGFP transgenic mouse bone marrow-transplanted ICR mice. We conclude that both the number of circulating EPCs and neo-vasculogenesis are increased in response to DPP-4 inhibitor treatment and that this occurs via an eNOS-dependent mechanism. The results highlight the therapeutic vasculogenesis potential of the DPP-4 inhibitor MK-0626 using a hind limb ischemia mouse model.
原文英語
頁(從 - 到)2012-2022
頁數11
期刊Current Medicinal Chemistry
21
發行號17
DOIs
出版狀態已發佈 - 2014

指紋

Dipeptidyl-Peptidase IV Inhibitors
Endothelial cells
Nitric Oxide Synthase
Nitric Oxide Synthase Type III
Ischemia
Extremities
Inbred ICR Mouse
Bone
Bone Marrow
Dipeptidyl Peptidase 4
Chemokine CXCL12
Phosphorylation
Glucagon-Like Peptide 1
Flow cytometry
MK0626
Endothelial Progenitor Cells
Thigh
Knockout Mice
Surgery
Transgenic Mice

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

引用此文

MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. / Shih, Chun Ming; Chen, Yung Hsiang; -Lin, Yi Wen; Tsao, Nai Wen; Wu, Shinn Chih; Kao, Yung Ta; Chiang, Kuang Hsing; Li, Chi Yuan; Chang, Nen Chung; Lin, Cheng Yen; Huang, Chun Yao; Lin, Feng Yen.

於: Current Medicinal Chemistry, 卷 21, 編號 17, 2014, p. 2012-2022.

研究成果: 雜誌貢獻文章

@article{40968644f5b1474dacb796c69594f990,
title = "MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression",
abstract = "Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic vasculogenesis may open an important new avenue for the treatment of CLI. This study examines the therapeutic potential of the DPP-4 inhibitor MK-0626 as a regulator of vasculogenesis in vivo. MK-0626 was administered daily to C57CL/B6 mice and eGFP-labeled bone marrow-transplanted ICR mice that had undergone hind limb ischemia surgery. Laser Doppler imaging and flow cytometry were used to evaluate the degree of neo-vasculogenesis and the number of circulating endothelial progenitor cells (EPCs), respectively. Cell surface markers of EPCs and the level of endothelial nitric oxide synthase (eNOS) were studied in the vessels. Mice that received MK-0626 had an elevated level of glucagon- like peptide-1 (GLP-1) and a decreased level of dipeptidyl peptidase-4 (DPP-4) in their plasma, in addition to an ischemia-induced increase in the level of stromal cell-derived factor-1 (SDF-1). In C57CL/B6 mice, blood flow in the ischemic limb was significantly improved by treatment with MK-0626. The number of circulating EPCs and both the synthesis and phosphorylation of eNOS were also increased in ischemic thigh muscle after MK-0626 treatment. In contrast, similar effects of MK-0626 were not observed in B6.129P2-Nos3tm1Unc/J mice (an eNOS knockout mouse). Additionally, MK-0626 treatment promoted the mobilization and homing of EPCs to ischemic tissue in eGFP transgenic mouse bone marrow-transplanted ICR mice. We conclude that both the number of circulating EPCs and neo-vasculogenesis are increased in response to DPP-4 inhibitor treatment and that this occurs via an eNOS-dependent mechanism. The results highlight the therapeutic vasculogenesis potential of the DPP-4 inhibitor MK-0626 using a hind limb ischemia mouse model.",
keywords = "Dipeptidyl peptidase-4, Endothelial nitric oxide synthase, Endothelial progenitor cells, Stromal cell-derived factor-1",
author = "Shih, {Chun Ming} and Chen, {Yung Hsiang} and -Lin, {Yi Wen} and Tsao, {Nai Wen} and Wu, {Shinn Chih} and Kao, {Yung Ta} and Chiang, {Kuang Hsing} and Li, {Chi Yuan} and Chang, {Nen Chung} and Lin, {Cheng Yen} and Huang, {Chun Yao} and Lin, {Feng Yen}",
year = "2014",
doi = "10.2174/09298673113206660273",
language = "English",
volume = "21",
pages = "2012--2022",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "17",

}

TY - JOUR

T1 - MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression

AU - Shih, Chun Ming

AU - Chen, Yung Hsiang

AU - -Lin, Yi Wen

AU - Tsao, Nai Wen

AU - Wu, Shinn Chih

AU - Kao, Yung Ta

AU - Chiang, Kuang Hsing

AU - Li, Chi Yuan

AU - Chang, Nen Chung

AU - Lin, Cheng Yen

AU - Huang, Chun Yao

AU - Lin, Feng Yen

PY - 2014

Y1 - 2014

N2 - Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic vasculogenesis may open an important new avenue for the treatment of CLI. This study examines the therapeutic potential of the DPP-4 inhibitor MK-0626 as a regulator of vasculogenesis in vivo. MK-0626 was administered daily to C57CL/B6 mice and eGFP-labeled bone marrow-transplanted ICR mice that had undergone hind limb ischemia surgery. Laser Doppler imaging and flow cytometry were used to evaluate the degree of neo-vasculogenesis and the number of circulating endothelial progenitor cells (EPCs), respectively. Cell surface markers of EPCs and the level of endothelial nitric oxide synthase (eNOS) were studied in the vessels. Mice that received MK-0626 had an elevated level of glucagon- like peptide-1 (GLP-1) and a decreased level of dipeptidyl peptidase-4 (DPP-4) in their plasma, in addition to an ischemia-induced increase in the level of stromal cell-derived factor-1 (SDF-1). In C57CL/B6 mice, blood flow in the ischemic limb was significantly improved by treatment with MK-0626. The number of circulating EPCs and both the synthesis and phosphorylation of eNOS were also increased in ischemic thigh muscle after MK-0626 treatment. In contrast, similar effects of MK-0626 were not observed in B6.129P2-Nos3tm1Unc/J mice (an eNOS knockout mouse). Additionally, MK-0626 treatment promoted the mobilization and homing of EPCs to ischemic tissue in eGFP transgenic mouse bone marrow-transplanted ICR mice. We conclude that both the number of circulating EPCs and neo-vasculogenesis are increased in response to DPP-4 inhibitor treatment and that this occurs via an eNOS-dependent mechanism. The results highlight the therapeutic vasculogenesis potential of the DPP-4 inhibitor MK-0626 using a hind limb ischemia mouse model.

AB - Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic vasculogenesis may open an important new avenue for the treatment of CLI. This study examines the therapeutic potential of the DPP-4 inhibitor MK-0626 as a regulator of vasculogenesis in vivo. MK-0626 was administered daily to C57CL/B6 mice and eGFP-labeled bone marrow-transplanted ICR mice that had undergone hind limb ischemia surgery. Laser Doppler imaging and flow cytometry were used to evaluate the degree of neo-vasculogenesis and the number of circulating endothelial progenitor cells (EPCs), respectively. Cell surface markers of EPCs and the level of endothelial nitric oxide synthase (eNOS) were studied in the vessels. Mice that received MK-0626 had an elevated level of glucagon- like peptide-1 (GLP-1) and a decreased level of dipeptidyl peptidase-4 (DPP-4) in their plasma, in addition to an ischemia-induced increase in the level of stromal cell-derived factor-1 (SDF-1). In C57CL/B6 mice, blood flow in the ischemic limb was significantly improved by treatment with MK-0626. The number of circulating EPCs and both the synthesis and phosphorylation of eNOS were also increased in ischemic thigh muscle after MK-0626 treatment. In contrast, similar effects of MK-0626 were not observed in B6.129P2-Nos3tm1Unc/J mice (an eNOS knockout mouse). Additionally, MK-0626 treatment promoted the mobilization and homing of EPCs to ischemic tissue in eGFP transgenic mouse bone marrow-transplanted ICR mice. We conclude that both the number of circulating EPCs and neo-vasculogenesis are increased in response to DPP-4 inhibitor treatment and that this occurs via an eNOS-dependent mechanism. The results highlight the therapeutic vasculogenesis potential of the DPP-4 inhibitor MK-0626 using a hind limb ischemia mouse model.

KW - Dipeptidyl peptidase-4

KW - Endothelial nitric oxide synthase

KW - Endothelial progenitor cells

KW - Stromal cell-derived factor-1

UR - http://www.scopus.com/inward/record.url?scp=84899872989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899872989&partnerID=8YFLogxK

U2 - 10.2174/09298673113206660273

DO - 10.2174/09298673113206660273

M3 - Article

VL - 21

SP - 2012

EP - 2022

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 17

ER -